Big,
. I hate to burst your bubble here but IMHO a
reality check is in order.
First, to use the word "biotech" in the same sentence with INVI is a
stretch. Determining the level of a product's corrosiveness by the
amount of time it takes to dissolve through INVI's proprietary
membrane is not rocket science and it certainly isn't a new miracle
drug.
Second, the stock was once above $13 per share because of the
demand for their test kits based on so called strict DOT guidelines
for the shipment of toxic chemicals. As it turned out, the new
guidelines had no "teeth", therefore, no need for the test kits. Will
the new DOT guidelines be any different.
Third, while i agree that animal testing needs to be eliminated,
there is a very firmly entrenched "good, old boy" school of thought
that has successfully resisted the change. It appears the legal
system prefers to defend companies that produce toxic materials
based on precedents established by animal testing. This will change
but will INVI be around long enough to benefit?
Lastly, INVI is on track to do a little over $520,000 in sales this year.
With 14 million shares outstanding and a price of .21 per share, INVI
has a market cap of $2.9 million. In other words, INVI is currently
valued at 5.6X sales. The only way you're going to see $3 - $5 per
share is if they sell their test kits over the internet or do a reverse
split.
Sorry if i seem a little skeptical here.
Regards,
danny |
